Skip to content

Investigating the effects and side effects of bupropion in multiple sclerosis patients

Investigating the effect and side effects of bupropion on fatigue, disability and quality of life of multiple sclerosis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190325043107N48
Enrollment
80
Registered
2024-08-10
Start date
2024-10-21
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of life. Multiple sclerosis

Interventions

Intervention 1: Intervention group: The patients of this group will be prescribed bupropion (150 mg/extended release product of Obidi company) once a day for six months in addition to routine treatmen

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of multiple sclerosis based on MacDonald criteria 2017 version EDSS value smaller than four

Exclusion criteria

Exclusion criteria: Taking drugs that have a reducing or intensifying effect on fatigue, such as dalfampridine, modafinil, antidepressants and other psychiatric drugs. Using other auxiliary methods such as herbal medicines, antidepressants, yoga, unnecessary supplements, addiction or drug use

Design outcomes

Primary

MeasureTime frame
Quality of life. Timepoint: Once every month for six months. Method of measurement: McGill Quality of Life Questionnaire.;Fatigue. Timepoint: Once every month for six months. Method of measurement: Physical examination and asking the patient himself.;Disability. Timepoint: Once every month for six months. Method of measurement: Physical examination and asking the patient himself.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRana Malek_Mohammadi

Tabriz University of Medical Sciences

Mkhanbabayi@yahoo.com+98 41 3335 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026